For research use only. Not for use in humans.

Cobolimab (Anti-TIM-3 / HAVCR2 / CD366)

Synonyms: HAVcr-2, CD366

Cobolimab (Anti-TIM-3 / HAVCR2 / CD366) is a monoclonal antibody against the inhibitory T-cell receptor, T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. MW : 145 KD.

Cobolimab (Anti-TIM-3 / HAVCR2 / CD366)

2 Citations

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: A280201 Purity: 99% Protein concentration: 19.95mg/ml Endotoxin Level: <1EU/mg
99

Specificity

Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Cobolimab (Anti-TIM-3 / HAVCR2 / CD366) is a monoclonal antibody against the inhibitory T-cell receptor, T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. MW : 145 KD.
References

Product Details

CAS No. 2022215-65-0
Molecular Weight 145
Isotype Human IgG4SP
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02817633 ACTIVE_NOT_RECRUITING Drug: TSR-022|Drug: Nivolumab|Drug: TSR-042|Drug: TSR-033|Dr Neoplasms Tesaro, Inc. 2016-07-08 PHASE1
NCT06056895 ACTIVE_NOT_RECRUITING Drug: Tuparstobart|Drug: Verzistobart Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8; Clinical Stage IV Merkel Cell Carcinoma AJCC v8; Merkel Cell Carcinoma University of Washington 2023-11-08 PHASE2
NCT06608940 WITHDRAWN Drug: BC3402|Drug: Durvalumab|Drug: Tremelimumab Hepato Cellular Carcinoma (HCC) Case Comprehensive Cancer Center 2025-11 PHASE1; PHASE2
NCT04446351 ACTIVE_NOT_RECRUITING Drug: GSK6097608|Drug: Dostarlimab|Drug: Cobolimab|Drug: Bel Neoplasms GlaxoSmithKline 2020-06-25 PHASE1
NCT05357651 RECRUITING Drug: LB1410 Solid Tumor; Lymphoma L & L Bio Co., Ltd., Ningbo, China 2022-08-12 PHASE1
NCT06238635 ACTIVE_NOT_RECRUITING Drug: Dostarlimab|Drug: Cobolimab Cervical Cancer; Advanced Cervical Carcinoma; Metastatic Cervical Cancer; Metastatic Cervical Carcinoma; Recurrent Cervical Carcinoma Meghan Shea 2024-03-11 PHASE2

(data from https://clinicaltrials.gov, updated on 2025-10-28)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.